









Markets
/
Stocks
/
nasdaq-gctk
/

GlucoTrack Inc

GCTK

1.000USD

-0.040-3.85%

Close 03/27, 16:00（ET）Quotes delayed by 15 min

4.07KMarket Cap

LossP/E TTM



GlucoTrack Inc

1.000

-0.040-3.85%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of GlucoTrack Inc

Currency: USD Updated: 2026-03-26

Key Insights

GlucoTrack Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 226 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is high.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

GlucoTrack Inc's Score

Industry at a Glance

Industry Ranking

226 / 391

Overall Ranking

487 / 4546

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

GlucoTrack Inc Highlights

StrengthsRisks

Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Overvalued

The company’s latest PE is -0.00, at a high 3-year percentile range.

Held by James Simons

Star Investor James Simons holds 0.00 shares of this stock.

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-26

The current financial score of GlucoTrack Inc is 6.89, ranking 172 out of 391 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.89

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.65

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

GlucoTrack Inc's Company Valuation

Currency: USD Updated: 2026-03-26

The current valuation score of GlucoTrack Inc is 6.35, ranking 288 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.00, which is -100.00% below the recent high of 0.00 and -26768287.50% above the recent low of -214.15.

Score

Industry at a Glance

Previous score

6.35

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 226/391

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-26

No earnings forecast score is currently available for GlucoTrack Inc. The Biotechnology & Medical Research industry's average is 8.07.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-26

The current price momentum score of GlucoTrack Inc is 3.43, ranking 363 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.47 and the support level at 0.86, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

3.40

Change

0.03

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.069

Neutral

RSI(14)

25.363

Sell

STOCH(KDJ)(9,3,3)

25.291

Buy

ATR(14)

0.092

High Vlolatility

CCI(14)

-45.174

Neutral

Williams %R

82.609

Oversold

TRIX(12,20)

-2.149

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.072

Sell

MA10

1.103

Sell

MA20

1.269

Sell

MA50

1.929

Sell

MA100

3.522

Sell

MA200

4.933

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-26

The current institutional shareholding score of GlucoTrack Inc is 3.00, ranking 195 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 0.76%, representing a quarter-over-quarter decrease of 0.17%. The largest institutional shareholder is James Simons, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

John A Ballantyne Rev Trust

45.73K

+0.00%

Balo (Andrew K)

1.28K

Malave (Luis)

2.82K

+19.62%

Alerus Financial, N.A.

5.00K

Geode Capital Management, L.L.C.

2.43K

Carter (Erin Catherine)

1.12K

+52.88%

Risk Assessment

Currency: USD Updated: 2026-03-26

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of GlucoTrack Inc is 1.91, ranking 264 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 0.47. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.